In some women, the estrogen in combination hormonal birth control methods increases the risk of a blood clot in a leg (deep vein thrombosis, or DVT) or a blood clot in a lung (pulmonary embolism, or PE). A blood clot in a leg vein can travel through the circulation system and cause pulmonary embolism.
The risk for DVT or PE is overall very low with hormonal contraceptives. In the past, combination birth control pills contained a higher dose of estrogen, which increased the risk of DVT and PE. Now the combination pill contains a lower dose of estrogen, and the risk is reduced. The risk for DVT or PE is actually higher for a pregnant women than for nonpregnant women taking hormonal contraceptives.
Combination hormonal birth control pills that contain the progestin called desogestrel increase the risk of blood clots more than birth control pills that contain other types of progestin.1 The progestin called drospirenone (found in pills such as YAZ or Yasmin) also might have a greater risk of blood clots than other types of progestin.2 Talk to your doctor about the risk of blood clots when deciding which pill is right for you.
The birth control patch delivers more estrogen than the low-dose birth control pills do. The U.S. Food and Drug Administration (FDA) warns that women using the patch are slightly more likely to get dangerous blood clots in the legs and lungs than women using birth control pills. So talk to your doctor about your risks before using the patch.
The known risk factors for blood clots (DVT or PE) include:3
- Abramowicz M (2010). Choice of contraceptives. Treatment Guidelines From the Medical Letter, 8(100): 89–96.
- U.S. Food and Drug Administration (2011). FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Available online: http://www.fda.gov/Drugs/DrugSafety/ucm299305.htm.
- American College of Obstetricians and Gynecologists (2006, reaffirmed 2008). Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 73. Obstetrics and Gynecology, 107(6): 1453–1472.
|Primary Medical Reviewer||Sarah Marshall, MD - Family Medicine|
|Specialist Medical Reviewer||Femi Olatunbosun, MB, FRCSC - Obstetrics and Gynecology|
|Last Revised||May 3, 2012|
Last Revised: May 3, 2012
Author: Healthwise Staff
To learn more visit Healthwise.org
© 1995-2013 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.